TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00979758

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Atorvastatin and mononuclear cells transplantation
Description: Routine or intensive dose of Atorvastatin therapy and mononuclear cells transplantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin and mononuclear cells transplantation
Description: Routine or intensive dose of Atorvastatin therapy and mononuclear cells transplantation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin and mononuclear cells transplantation
Description: Routine or intensive dose of Atorvastatin therapy and mononuclear cells transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin and mononuclear cells transplantation
Description: Routine or intensive dose of Atorvastatin therapy and mononuclear cells transplantation
Study: NCT01946880

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Subjects will enter the trial on 1000-3000 mg/day of MMF and will be randomized to remain on MMF treatment or to be tapered off MMF within 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Subjects will enter the trial on 1000-3000 mg/day of MMF and will be randomized to remain on MMF treatment or to be tapered off MMF within 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine or Chloroquine
Description: Subjects will be on concurrent anti-malarial agents (hydroxychloroquine or chloroquine). Hydroxychloroquine is approved by the FDA for the treatment of SLE. Hydroxychloroquine has been shown to help prevent flare in SLE, and to improve skin and musculoskeletal activity in particular.Even lupus nephritis outcomes appear improved on a background of hydroxychloroquine therapy
Study: NCT02556203

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 75mg OD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: In case of NOAF, 20/15 mg OD (once-daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K antagonist (VKA)
Description: In case of NOAF, Open-label VKA therapy to target international normalized ratio (INR) 2-3, according to guidelines
Study: NCT01466374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-936557 (Anti-IP-10 Antibody)
Description: Solution for IV administration, Intravenous, 10 mg/kg, Once a week for the first week and every other week thereafter, 11 weeks
Study: NCT01946880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine or Chloroquine
Description: Subjects will be on concurrent anti-malarial agents (hydroxychloroquine or chloroquine). Hydroxychloroquine is approved by the FDA for the treatment of SLE. Hydroxychloroquine has been shown to help prevent flare in SLE, and to improve skin and musculoskeletal activity in particular.Even lupus nephritis outcomes appear improved on a background of hydroxychloroquine therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Once the subject is randomized into the trial, the prednisone (or other corticosteroid) dose must be stable through Week 36 (24 weeks following protocol taper of MMF), in the absence of flares as described in Section 3.2 of the study protocol, Description of Primary Endpoint. Further taper of prednisone after that point is by the investigator's discretion based on the subject's clinical status.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Once the subject is randomized into the trial, the prednisone (or other corticosteroid) dose must be stable through Week 36 (24 weeks following protocol taper of MMF), in the absence of flares as described in Section 3.2 of the study protocol, Description of Primary Endpoint. Further taper of prednisone after that point is by the investigator's discretion based on the subject's clinical status.
Study: NCT01943773

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional Assessment
Description: Both arms of the study will undergo functional assessments at three points during the study progress.~BASELINE ASSESSMENT: On study entry, each participant will have a timed up-and-go, Mini Mental Status Exam, de Morton, Modified Physical Performance Test (MPPT), and a short physical performance battery performed.~ASSESSMENT OF INTERVENTION EFFECTIVENESS:~Immediately prior to the operation, all participants will undergo repeat testing. The difference in scores between the preoperative assessment and the initial assessment at enrollment will be compared in the control and intervention groups.~POST-OPERATIVE ASSESSMENT: Repeat testing will be performed 60 days following the operation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional Assessment
Description: Both arms of the study will undergo functional assessments at three points during the study progress.~BASELINE ASSESSMENT: On study entry, each participant will have a timed up-and-go, Mini Mental Status Exam, de Morton, Modified Physical Performance Test (MPPT), and a short physical performance battery performed.~ASSESSMENT OF INTERVENTION EFFECTIVENESS:~Immediately prior to the operation, all participants will undergo repeat testing. The difference in scores between the preoperative assessment and the initial assessment at enrollment will be compared in the control and intervention groups.~POST-OPERATIVE ASSESSMENT: Repeat testing will be performed 60 days following the operation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: The intervention will consist of nine 45 minute long physical therapy sessions.
Study: NCT01466374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-936557 (Anti-IP-10 Antibody)
Description: Solution for IV administration, Intravenous, 20 mg/kg, Once a week for the first week and every other week thereafter, 11 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-936557 (Anti-IP-10 Antibody)
Description: Solution for IV administration, Intravenous, 7.5 mg/kg, Every other week, Up to 337 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-936557 (Anti-IP-10 Antibody)
Description: Solution for IV administration, Intravenous, 15 mg/kg, Every other week, Up to 337 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-936557 (Anti-IP-10 Antibody)
Description: Solution for IV administration, Intravenous, 15 mg/kg or optimal dose, Every other week, Open
Study: NCT03090412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPPH
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03585309

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The impact of electrocoagulation on ovarian reserve after laparoscopic excision of ovarian cysts:
Description: Randomization Randomization will be conducted using computer generated table. Group A (48 CASES) without coagulation~Group A 6 89 92 35 1 15 21 16 60 49 53 91 34 5 94 64 88 58 7 33 8 75 29 56 10 23 37 19 32 71 55 84 36 77 50 2 46 70 82 9 51 54 72 18 25 31 14 63~Group B (48 CASES) with coagulation Group B 79 38 93 43 52 44 62 47 68 76 86 95 81 83 42 80 94 30 78 61 12 17 66 13 41 59 22 73 39 65 4 90 28 26 3 87 40 85 69 48 27 24 74 57 11 20 67 45~Allocation and concealment Nineteen six opaque envelopes will be numbered serially and in each envelope the corresponding letter which denotes the allocated group will be put according to randomization table then all envelopes will be closed and put in one box. When the first patient arrives the first envelope will be opened and the patient will be allocated according to the letter inside.
Study: NCT01843257

Intervention type: OTHER
Intervention: Alcohol challenge test Alcohol visit first
Description: Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 alcohol, visit 2 placebo).

Intervention type: OTHER
Intervention: Alcohol challenge test Alcohol visit first
Description: Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 alcohol, visit 2 placebo).
Study: NCT03090412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Description: Undergo PDT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo standard of care surgery
Study: NCT00739999

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Description: 6-10 years Tanner Stage 1 will be administered 5-mg daily dose of an atorvastatin pediatric tablet formulation. Dose may be doubled if subjects have not attained target LDL (\<3.35 mmol/L) after 4-week treatment.
Study: NCT02427399

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Letter and informational sheet
Description: The patients in this group will be mailed a letter at time 0. The letter will inform the patient that she is overdue for a Pap and will also contain an informational sheet about cervical cancer and Pap tests.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Email
Description: The same text shared in the letter will be sent as an email to the patients in this intervention group, again at time 0, 1, and 2 months, as necessary for nonresponders.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone
Description: The patient will be telephoned and informed that they are due for a Pap, and given the opportunity to schedule an appointment over the phone immediately. Patients will be contacted at time 0, 1, and 2 months as necessary for nonresponders.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal
Description: The patient will be sent a letter/informational sheet at time 0. If she does not respond within one month, she will be sent an email. If she does not respond by 2 months after the start of the intervention period, she will be called.
Study: NCT00115869

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social-influences
Description: grades 3-10, school-based social influences tobacco use prevention curriculum
Study: NCT02937207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ke Chuan Liu Wei Mixture
Description: Experience formula of famous traditional Chinese professor Yingen Wu

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chuan Xiong Ping Chuan Mixture
Description: Experience formula of famous traditional Chinese professor Changrong Shao

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xie Wu Capsule
Description: Experience formula of famous traditional Chinese professor Jianhua Hu

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dan Ma Jia Tablet
Description: Experience formula of famous traditional Chinese professor Xiaopu Xu

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zhi Chuan Capsule
Description: Experience formula of famous traditional Chinese professor Yingen Wu

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bu Shen Na Qi Granule
Description: Experience formula of famous traditional Chinese professor Changrong Shao

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ke Chuan Liu Wei Mixture placebo
Description: Low dose combination for treating prescription of Ke Chuan Liu Wei Mixture

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chuan Xiong Ping Chuan Mixture placebo
Description: Low dose combination for treating prescription of Chuan Xiong Ping Chuan Mixture

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Xie Wu Capsule placebo
Description: Low dose combination for treating prescription of Xie Wu Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dan Ma Jia Tablet placebo
Description: Low dose combination for treating prescription of Dan Ma Jia Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zhi Chuan Capsule placebo
Description: Low dose combination for treating prescription of Zhi Chuan Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bu Shen Na Qi Granule placebo
Description: Low dose combination for treating prescription of Bu Shen Na Qi Granule
Study: NCT03824834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exercise training with morphine
Description: Immediate-release oral morphine (syrup, 0.1 mg/kg body mass to a maximum dose of 10 mg) prepared in 250 mL of orange juice 30-min prior to each exercise session. Participants will complete exercise training sessions (three times per week for five weeks) on an electronically braked bike, supervised by a trained exercise specialist. Exercise sessions will be individualized based on participants' peak power output (60% PPO) determined from incremental exercise testing, and progressed to ensure the participant is exercising at a breathlessness intensity rating of between 3-5 Borg CR10 scale units and can complete at least 20-min of continuous cycling. Exercise duration will be increased in 5-min intervals up to 40-min. Thereafter, exercise intensity will be increased by 5-15% of baseline PPO.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise training with placebo
Description: Diluted simple syrup prepared in 250 mL of orange juice 30-min prior to each exercise session. Participants will complete exercise training sessions as per the experimental group.
Study: NCT03670719

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy and Exercise
Description: Combination of physiotherapy (manual therapy) techniques and exercises for the cervical spine
Study: NCT00739999

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Description: 10-17 years Tanner Stage 2 will be administered 10-mg daily dose of atorvastatin tablet formulation. Dose may be doubled if subjects have not attained target LDL (\<3.35 mmol/L) after 4-week treatment.
Study: NCT01397591

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given intravenously
Study: NCT03908047

Intervention type: OTHER
Intervention: magnetic resonance imaging
Description: functional magnetic resonance imaging and diffusion tensor imaging after tibialis nerve stimulation
Study: NCT03377036

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: DBT+s2D
Description: Digital breast tomosynthesis plus synthesized 2D mammograms

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 2D-FFDM
Description: 2D full-field digital mammography
Study: NCT00507611

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sentinel node mapping
Description: Patients will undergo preoperative lymphoscintigraphy in the nuclear medicine department to access axillary and extra-axillary sites of localization. Intraoperatively, patients will also be injected with approximately 4 to 5 mL of 1% isosulfan blue dye (by intradermal, intraparenchymal, or subareolar route). Patients will undergo intraoperative identification and biopsy of all SLN candidates. A confirmatory axillary lymph node dissection will then be performed on all patients.
Study: NCT00518752

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Oral Care
Description: Patients in this arm will receive standard oral care with manual brushes and routine oral hygiene products twice a day

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comprehensive Oral Care
Description: Patients will receive a comprehensive oral care protocol using mechanical brushes and oral care products formulated for patients with a dry mouth twice a day
Study: NCT01636362

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepitel Ag
Description: Mepitel Ag is an antimicrobial, meshed, non-adherent wound contact layer allowing passage of exudate and providing fixation and protection of tissues.
Study: NCT04230161

Intervention type: OTHER
Intervention: Standard long-lasting insecticidal net
Description: Yahe LN (Yamei Industry) contains a pyrethroid insecticide.

Intervention type: OTHER
Intervention: Standard long-lasting insecticidal net
Description: Yahe LN (Yamei Industry) contains a pyrethroid insecticide.

Intervention type: OTHER
Intervention: Chlorfenapyr insecticide treated net
Description: Interceptor G2® (BASF) is an ITN containing two active ingredients: Alpha-cypermethrin, a pyrethroid insecticide, and chlorfenapyr, a pyrrole insecticide.

Intervention type: OTHER
Intervention: Indoor residual spraying
Description: Fludora Fusion (Bayer Vector Control) is a spray containing two active ingredients: clothianidin, a neonicotinoid insecticide, and deltamethrin, a pyrethroid insecticide.
Study: NCT00251173

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strengths Based Case Management (SBCM)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Enhancement Therapy (MET)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Informational Feedback (BIF) session
Study: NCT02616848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Study: NCT02497612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferroquine SSR97193
Description: Pharmaceutical form:Capsules Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferroquine SSR97193
Description: Pharmaceutical form:Capsules Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferroquine SSR97193
Description: Pharmaceutical form:Capsules Route of administration: oral
Study: NCT04000893

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance exercise session
Description: Acute isometric exercise session performed with handgrip Jamar about 20 minutes monitored.
Study: NCT02497612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferroquine SSR97193
Description: Pharmaceutical form:Capsules Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artefenomel
Description: Pharmaceutical form:Granules for suspension Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artefenomel
Description: Pharmaceutical form:Granules for suspension Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artefenomel
Description: Pharmaceutical form:Granules for suspension Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artefenomel
Description: Pharmaceutical form:Granules for suspension Route of administration: oral

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules. Placebo capsules were used to keep the same number of capsules in each weight band while keeping the ferroquine dose blinded. No participant received placebo only.
Study: NCT03403790

Intervention type: DRUG
Intervention: Quetiapine
Description: Oral (extended-release tablet)
Study: NCT02497612

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules. Placebo capsules were used to keep the same number of capsules in each weight band while keeping the ferroquine dose blinded. No participant received placebo only.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules. Placebo capsules were used to keep the same number of capsules in each weight band while keeping the ferroquine dose blinded. No participant received placebo only.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules. Placebo capsules were used to keep the same number of capsules in each weight band while keeping the ferroquine dose blinded. No participant received placebo only.
Study: NCT00443027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal Heat Wash-Out Device
Description: No drug administered. Device tested three times with each subject.
Study: NCT03670719

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercises for the cervical spine
Study: NCT02227550

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K antagonist
Description: any locally used VKA, INR 2-3, min. 30 days according to aplicable medical guidelines and local clinical routin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: factor Xa inhibitor Apixaban min. 30 days 5 mg twice daily (fix dose) dose reduction Apixaban 2,5 mg twice daily in patients who fulfill tow of the following criteria at the time of randomisation: chronic kidney disease (serum creatine \>= 1.5 mg/dl (133mM), \<= 60 kg body weight or age \>= 80 years.
Study: NCT04911205

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative training program
Description: Patients of intervention group (N=44) followed a 6-week supervised high-intensity preoperative training program. They had a session of preoperative resistance training five days per week for a period of 6 weeks before TKA. Each session was supervised by a physiotherapist specifically trained in progressive resistance training. The duration of each session was approximately 60 minutes. If a participant missed a training session, it was attempted to substitute the session on an alternative day.